Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01487083 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study in Schizophrenia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
NCT01487083: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT01487083 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 282 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01487083, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of pomaglumetad methionil in participants with schizophrenia.
Interventions
- DRUG Pomaglumetad methionil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Why NCT01487083 stopped before completion
NCT01487083 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which Pomaglumetad methionil is the first listed.
NCT01487083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01487083 about?
NCT01487083 is a clinical study titled "A Long-Term Study in Schizophrenia". The purpose of this study is to evaluate the long-term safety of pomaglumetad methionil in participants with schizophrenia.
What is the current status of trial NCT01487083?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2011-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01487083?
The interventions under investigation include: Pomaglumetad methionil (DRUG).
Who is sponsoring clinical trial NCT01487083?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01487083's enrollment target sits among peer trials
282 1194th of 2000 higher than 807 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia